Cardiff Oncology, Inc. financial data

Symbol
CRDF on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
11055 Flintkote Avenue, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Trovagene, Inc. (to 5/7/2020), TrovaGene Inc. (to 3/4/2013), XENOMICS INC (to 6/3/2009), USED KAR PARTS INC (to 6/30/2004)
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 568 % -50.3%
Debt-to-equity 22.5 % +99.3%
Return On Equity -74 % -66.5%
Return On Assets -60.4 % -51.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 51.1M shares +14.5%
Common Stock, Shares, Outstanding 48.7M shares +9.07%
Entity Public Float 64.3M USD -31.4%
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 46.9M shares +4.9%
Weighted Average Number of Shares Outstanding, Diluted 46.9M shares +4.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 689K USD +49.8%
Operating Income (Loss) -46.4M USD -4.36%
Nonoperating Income (Expense) 3.43M USD -6.57%
Net Income (Loss) Attributable to Parent -43M USD -5.34%
Earnings Per Share, Basic -0.94 USD/shares -2.17%
Earnings Per Share, Diluted -0.94 USD/shares -2.17%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 13M USD -14.4%
Cash, Cash Equivalents, and Short-term Investments 57.7M USD -29.1%
Accounts Receivable, after Allowance for Credit Loss, Current 618K USD +212%
Assets, Current 59.3M USD -29.3%
Property, Plant and Equipment, Net 993K USD -24.6%
Operating Lease, Right-of-Use Asset 1.3M USD -29.2%
Other Assets, Noncurrent 1.27M USD -8.65%
Assets 62.9M USD -28.9%
Accounts Payable, Current 4.64M USD +113%
Employee-related Liabilities, Current 1.99M USD -18.8%
Accrued Liabilities, Current 7.18M USD +16.6%
Liabilities, Current 12.5M USD +38.9%
Operating Lease, Liability, Noncurrent 979K USD -39.1%
Liabilities 13.5M USD +27.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 82K USD
Retained Earnings (Accumulated Deficit) -372M USD -12.8%
Stockholders' Equity Attributable to Parent 49.4M USD -36.5%
Liabilities and Equity 62.9M USD -28.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.74M USD +10.6%
Net Cash Provided by (Used in) Financing Activities 107K USD
Net Cash Provided by (Used in) Investing Activities 4.64M USD -36.7%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 48.7M shares +9.07%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3M USD -125%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 13M USD -14.4%
Deferred Tax Assets, Valuation Allowance 39.2M USD +30.2%
Deferred Tax Assets, Gross 39.5M USD +29.3%
Operating Lease, Liability 2.15M USD -20.8%
Payments to Acquire Property, Plant, and Equipment 80K USD +900%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -42.5M USD -5.1%
Lessee, Operating Lease, Liability, to be Paid 2.4M USD -23.6%
Property, Plant and Equipment, Gross 5.05M USD +1.37%
Operating Lease, Liability, Current 707K USD +2.76%
Lessee, Operating Lease, Liability, to be Paid, Year Two 775K USD +2.79%
Lessee, Operating Lease, Liability, to be Paid, Year One 691K USD +2.22%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 249K USD -41%
Lessee, Operating Lease, Liability, to be Paid, Year Three 796K USD +2.71%
Deferred Tax Assets, Operating Loss Carryforwards 23.4M USD +15.5%
Preferred Stock, Shares Authorized 20M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 136K USD -82.9%
Operating Lease, Payments 730K USD +1.96%
Additional Paid in Capital 422M USD +3.25%
Depreciation, Depletion and Amortization 102K USD +13.3%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 4.47M USD -3.19%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%